m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01690)
Name
AdcAhxArg4NH(CH2)6NH2
Synonyms
CHEMBL263964
    Click to Show/Hide
Status
Investigative
Structure
3D MOL
2D MOL
Formula
C46H84N24O9
InChI
1S/C46H84N24O9/c47-17-5-1-2-6-18-57-37(74)26(12-8-20-59-43(49)50)67-39(76)28(14-10-22-61-45(53)54)69-40(77)29(15-11-23-62-46(55)56)68-38(75)27(13-9-21-60-44(51)52)66-30(71)16-4-3-7-19-58-41(78)34-32(72)33(73)42(79-34)70-25-65-31-35(48)63-24-64-36(31)70/h24-29,32-34,42,72-73H,1-23,47H2,(H,57,74)(H,58,78)(H,66,71)(H,67,76)(H,68,75)(H,69,77)(H2,48,63,64)(H4,49,50,59)(H4,51,52,60)(H4,53,54,61)(H4,55,56,62)/t26-,27-,28-,29-,32-,33+,34-,42+/m0/s1
InChIKey
AKYVNHGFJFUSDY-HYKQOWLKSA-N
PubChem CID
44387500
TTD Drug ID
D00OCS
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
cAMP-dependent protein kinase A type I (PRKAR1A)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary cAMP-dependent protein kinase A type I (PRKAR1A) is a therapeutic target for AdcAhxArg4NH(CH2)6NH2. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of AdcAhxArg4NH(CH2)6NH2 through regulating the expression of cAMP-dependent protein kinase A type I (PRKAR1A). [1], [2]
References
Ref 1 FTO-Dependent N (6)-Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling. Cancer Res. 2020 Aug 15;80(16):3200-3214. doi: 10.1158/0008-5472.CAN-19-4044. Epub 2020 Jun 30.
Ref 2 Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9. doi: 10.1016/s0960-894x(03)00641-3.